Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.23 million versus the consensus estimate of $2.2 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.